Why Zebra’s new healthcare push matters for investors
Zebra Technologies (ZBRA) has launched its Orchestrated Care framework and new DS82 HC Series scanner at the HIMSS26 health IT conference, putting fresh attention on how its healthcare focus could influence the stock.
The announcement comes as Zebra embeds artificial intelligence into products and internal processes, while also working to manage margin pressures from memory costs and supply chain challenges.
See our latest analysis for Zebra Technologies.
Despite the AI and healthcare announcements, the share price has had a weak spell, with a 30 day share price return of 22.92% and a five year total shareholder return of 56.02% decline. This hints that sentiment remains cautious even as Zebra pushes deeper into digital automation for hospitals.
If you like the healthcare tech angle but want to see what else is out there, this is a good moment to scan the market using our healthcare focused AI stock screener, starting with 33 healthcare AI stocks.
With Zebra’s shares posting a 1 year total return decline of 28.50% and trading at a 51.02% intrinsic discount, the key question now is whether this is a genuine reopening for buyers or if the market already reflects future growth.
Most Popular Narrative: 39.4% Undervalued
With Zebra Technologies last closing at $203.97 against a narrative fair value of $336.38, the current pricing sits well below what this widely followed model suggests, putting more focus on how its future automation and AI story is being translated into numbers.
The accelerating shift toward automation, digital transformation, and real-time workflow optimization, driven by ongoing labor shortages, e-commerce expansion, and increased supply chain demands, continues to fuel robust demand for Zebra's portfolio (hardware, software, RFID, machine vision), supporting sustained revenue growth and long-term earnings visibility.
Want to see how this demand story turns into a higher fair value? The narrative leans on steadier revenue, fatter margins, and a richer earnings multiple. Curious which specific growth and profitability assumptions have to hold up for that gap to close?
Result: Fair Value of $336.38 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, that fair value gap can shrink quickly if hardware reliant revenue proves bumpier than expected or if acquisitions in competitive markets drag on margins.
Find out about the key risks to this Zebra Technologies narrative.
Next Steps
With sentiment split between concern and optimism, this is a good moment to look through the numbers yourself and move quickly. Start by weighing the 4 key rewards and 1 important warning sign.
Looking for more investment ideas?
If Zebra has your attention, do not stop here. Use the screener to quickly surface other stocks that could better match your risk, income, or value goals.
- Target reliable cash generators by scanning companies with strong finances and manageable risk using the solid balance sheet and fundamentals stocks screener (42 results).
- Hunt for price gaps where quality and valuation might not match yet by working through the 47 high quality undervalued stocks.
- Boost the income side of your portfolio by reviewing higher yielding opportunities found in the 15 dividend fortresses.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com